Venturi Wealth Management LLC Raises Holdings in Insulet Co. (NASDAQ:PODD)

Venturi Wealth Management LLC boosted its position in Insulet Co. (NASDAQ:PODD - Free Report) by 1,047.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,767 shares of the medical instruments supplier's stock after purchasing an additional 1,613 shares during the period. Venturi Wealth Management LLC's holdings in Insulet were worth $461,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 58 shares during the last quarter. Friedenthal Financial bought a new position in shares of Insulet during the fourth quarter valued at about $57,000. TD Private Client Wealth LLC grew its position in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after buying an additional 56 shares during the last quarter. Versant Capital Management Inc boosted its position in Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock valued at $80,000 after acquiring an additional 157 shares in the last quarter. Finally, Quarry LP lifted its position in Insulet by 26.4% during the 3rd quarter. Quarry LP now owns 354 shares of the medical instruments supplier's stock valued at $82,000 after acquiring an additional 74 shares during the period.

Analysts Set New Price Targets

A number of brokerages have commented on PODD. Wells Fargo & Company upped their target price on shares of Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a report on Friday. BTIG Research lifted their target price on Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Canaccord Genuity Group lifted their price target on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a report on Friday. Piper Sandler increased their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday. Finally, Stifel Nicolaus raised their price target on Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $289.06.

Insulet Trading Down 1.8 %

Shares of Insulet stock traded down $5.18 during trading on Friday, hitting $283.12. The stock had a trading volume of 880,492 shares, compared to its average volume of 557,859. The stock has a market cap of $19.86 billion, a PE ratio of 48.46, a PEG ratio of 3.56 and a beta of 1.23. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The firm's fifty day simple moving average is $272.71 and its 200-day simple moving average is $246.47. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. As a group, sell-side analysts expect that Insulet Co. will post 3.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company's stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.